Clinical trials of a vaccine against Alzheimer disease came to an abrupt halt this year when several patients developed inflammation in the brain. Now, the first data from the trial and a mouse study brighten the outlook for this spectacular and simple treatment approach (pages 1263–1269 and 1270–1275).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hock, C. et al. Generation of anti-amyloid antibodies by vaccination of patients with Alzheimer's disease. Nature Med. 8, 1270–1275 (2002).
McLaurin, J.A. et al. Therapeutically effective anti-Aβ antibodies target Aβ residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nature Med. 8, 1263–1269 (2002).
Check, E. Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462 (2002).
Haass, C. & Steiner, H. Alzheimer's disease γ-secretase, a multicomponent complex involving presenilin proteases of the GxGD type. Trends Cell Biol. (in the press).
Walsh, D.M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
Weihofen, A., Binns, K., Lemberg, M.K., Ashman, K. & Martoglio, B. Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296, 2215–2218 (2002).
Cai, H. et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nature Neurosci. 4, 233–234 (2001).
Luo, Y. et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nature Neurosci. 4, 231–232 (2001).
Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916–919 (2000).
DeMattos, R.B. et al. Peripheral anti-Aβ antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855 (2001).
Solomon, B., Koppel, R., Frankel, D. & Hanan-Aharon, E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA 94, 4109–4112 (1997).
Morgan, D. et al. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982–985 (2000).
Janus, C. et al. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982 (2000).
Smith, M.A., Atwood, C.S., Joseph, J.A. & Perry, G. Predicting the failure of amyloid-β vaccine. Lancet 359, 1864–1865 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haass, C. New hope for Alzheimer disease vaccine. Nat Med 8, 1195–1196 (2002). https://doi.org/10.1038/nm1102-1195
Issue Date:
DOI: https://doi.org/10.1038/nm1102-1195
This article is cited by
-
Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development
Neuropsychopharmacology (2012)
